Payers Like Biosimilars, But Rebates Remain The Bottom Line (For Now)

 
• By Jessica Merrill
  
Businessman
Remicade biosimilar case reveals cavernous market challenges • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Drug Pricing

More from Scrip